Physiomics PLC Notice of AGM (4234Q)
18 Octubre 2023 - 1:00AM
UK Regulatory
TIDMPYC
RNS Number : 4234Q
Physiomics PLC
18 October 2023
18 October 2023
Physiomics plc
("Physiomics" or "the Company")
Notice of AGM
Physiomics plc (AIM: PYC), the oncology consultancy using
mathematical models to support the development of cancer treatment
regimens and personalised medicine solutions, is pleased to provide
notice of the Company's Annual General Meeting ("AGM").
The AGM will be held at 10.30 a.m. on 21 November 2023 at the
Company's new registered office, Bee House, 140 Eastern Avenue,
Milton Park, Oxfordshire, OX14 4SB.
Shareholders will shortly be sent either printed copies of the
Notice of AGM and accompanying materials or a letter notifying them
that they are available on the Company's website, depending on the
preferences they have expressed to the Company's registrar.
A copy of the Notice of AGM, containing further details of the
resolutions, as well as a copy of the Company's Annual Report and
Accounts will be made available today on the Company's website at
www.physiomics.co.uk/investors/reports-prospectus/ .
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
Hybridan LLP (Broker)
Claire Louise Noyce
+44 (0) 203 764 2341
Strand Hanson Ltd (NOMAD)
James Dance & James Bellman
+44 (0)20 7409 3494
Notes to Editor
About Physiomics
Physiomics plc combines cutting edge PKPD and QSP modelling
techniques with cancer biology expertise, to help biotech and
pharma companies streamline their drug development journeys.
Our approach is to derive insight from all relevant data in
order to de-risk decision making and optimise design of
pre-clinical and clinical studies.
Through use of bespoke models and our proprietary Virtual Tumour
technology, the Physiomics team has informed the development of
over 100 commercial projects, over 50 targets and 75 drugs. Clients
include Merck KGaA, Astellas, Bicycle Therapeutics, Numab
Therapeutics & CRUK.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NOAGZMMGDNLGFZM
(END) Dow Jones Newswires
October 18, 2023 02:00 ET (06:00 GMT)
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Physiomics (LSE:PYC)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
